Respiratory Syncytial Virus (RSV) Clinical Trial
Official title:
Estimation of Prevalence of and Risk Factor for Respiratory Viruses Among Emergently Admitted Adult Patients With Respiratory Symptoms and Their Influence on Clinical Outcomes in the Settings From Rural to Urban Community Hospitals
Study design is multicenter prospective registry study. Participants are consecutive (non-selected, a sequential registration) patients admitted from emergency rooms of participating hospitals who meet the eligibility criteria. The primary objectives are to estimate the prevalence of and risk factors for RS and other respiratory virus infection and their effect on hospital course in patients with any respiratory symptom who admit from emergency room using a multicenter prospective registry study. The primary target virus is RS virus and the secondary target viruses are respiratory virus and other microorganisms measured by FilmArray 2.1.
The investigators register consecutive patients who meet the eligibility criteria at 3 participating hospitals from electronic medical records. As a routine clinical practice, presence of respiratory symptoms using standard electronic medical record (EMR) format are universally assessed at the emergency room when the patients are determined to be admitted. Patients are registered if they meet the eligibility criteria and information of medical history, baseline characteristics, living status, physical findings, laboratory tests, chest X-ray, electrocardiogram, on admission are retrieved from the EMRs. The nasopharyngeal swab is obtained within 24 hours after admission as a standard practice, which will be sampled at either emergency rooms or hospital wards. The swab is transferred to the onsite laboratory office to measure the FilmArray 2.1 by trained technicians or physicians in charge. Serum antibodies for RS virus are obtained from patients with suspected lower respiratory infection (bronchitis and pneumonia) who provided their written informed consent, at the timing of admission and 4 weeks after the admission. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02593071 -
Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.
|
Phase 2 | |
| Completed |
NCT02282982 -
Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis
|
N/A | |
| Completed |
NCT02266628 -
Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults
|
Phase 2 | |
| Completed |
NCT01709019 -
RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly
|
Phase 1 | |
| Completed |
NCT01704365 -
RSV-F Vaccine Dose Ranging Study in Young Women
|
Phase 2 | |
| Recruiting |
NCT06185647 -
Evaluation in Practice of the Impact of NIrsevimab on EmeRgency Use for BRONCHIOlitis
|
||
| Recruiting |
NCT04925310 -
Infection With Respiratory Syncytial Virus in Infants
|
||
| Completed |
NCT02968173 -
A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus
|
Phase 3 | |
| Active, not recruiting |
NCT06077149 -
Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)
|
Phase 4 | |
| Completed |
NCT02608502 -
A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults
|
Phase 3 | |
| Recruiting |
NCT05047549 -
Community-based RSV Surveillance in Infant Mortality: Minimally Invasive Tissue Sampling Study in Karachi, Pakistan
|
||
| Terminated |
NCT04225897 -
A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection.
|
Phase 2 | |
| Recruiting |
NCT06216093 -
Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years
|
Phase 1 | |
| Not yet recruiting |
NCT06392451 -
LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia
|
N/A | |
| Completed |
NCT04927793 -
Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects
|
Phase 1 | |
| Active, not recruiting |
NCT05443607 -
Transplacental Transmission of RSV (TTRSV)
|
||
| Recruiting |
NCT04896853 -
Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®
|
Phase 1 | |
| Completed |
NCT03916185 -
Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT05842967 -
A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease
|
Phase 3 | |
| Recruiting |
NCT04909021 -
Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months
|
Phase 1 |